We refer to email dated 18/May/2026, referring to discrepancies in financial results for the QUARTER and financial year ended 31/March/2026. We hereby submit the financial results for ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sudarshan Pharma Industries has resubmitted its audited standalone and consolidated financial results for the half-year and full year ended 31 March 2026 after BSE flagged discrepancies. Standalone profit after tax stood at approximately Rs. 9.79 crore (vs Rs. 14.02 crore in the prior year), while consolidated PAT was about Rs. 10.29 crore (vs Rs. 14.93 crore), reflecting a year-on-year decline of roughly 30%. The company voluntarily adopted Ind AS for the first time from April 2025 with transition date April 2024. Auditor NGST & Associates issued an unmodified (clean) opinion on both sets of results. Key developments include winning a Dubai court award of about Rs. 90.19 crore against Regans International DMCC (of which Rs. 4.65 crore has been received), approval to raise up to Rs. 1,500 crore via Foreign Currency Convertible Bonds (FCCB), and acquisition of an API manufacturing facility from Srigen Lifesciences in Telangana for Rs. 25.5 crore.
Profitability has weakened noticeably compared to the previous year, which may weigh on the stock in the short term. However, the clean audit opinion, acquisition activity, and potential large fund raise signal management's growth ambitions. Investors should monitor progress on the FCCB issue and recovery of the remaining Dubai award amount as key catalysts.